Meta-analysis of 3,700 patients shows lobectomy and sub-lobar resection yield comparable overall survival for lung neuroendocrine tumors.

This systematic review and meta-analysis aggregated data from studies involving 3,700 patients with lung neuroendocrine tumors to evaluate the impact of surgical extent on patient outcomes. The primary comparison focused on overall survival between lobectomy and sub-lobar resection, which encompasses segmentectomy and wedge resection. The analysis aimed to determine whether the more extensive lobectomy provides a survival advantage over less extensive sub-lobar approaches in this specific tumor population. The follow-up period for the pooled data extended to 60.0 months, providing a medium-to-long-term perspective on survival outcomes.

The primary outcome measure was overall survival. The pooled 5-year overall survival for the entire cohort was 78.8% (95% CI, 76.6-81.1). When comparing lobectomy directly against sub-lobar resection as a group, the analysis found no statistically significant difference in overall survival. The hazard ratio was 1.21 with a 95% confidence interval of 0.80-1.83. When the sub-lobar group was stratified, segmentectomy demonstrated comparable survival to lobectomy, with a p-value of 0.38. Conversely, wedge resection was associated with higher mortality, yielding a hazard ratio of 2.02 (95% CI, 1.64-2.49). These data indicate that while lobectomy and segmentectomy appear to offer similar survival benefits, wedge resection may carry a higher risk of mortality.

Secondary outcomes examined the extent of lymph node assessment and pathological staging. Sampling of more than 10 lymph nodes was significantly more frequent in the lobectomy group compared to the sub-lobar resection group, with rates of 29.1% versus 7.4%, respectively. The 95% confidence intervals for these proportions were 0.8-95.3 for lobectomy and 0.01-98 for sub-lobar resection. Additionally, nodal pathologic upstaging occurred at a higher rate in the lobectomy group (6.2%) compared to the sub-lobar resection group (2.2%), although the wide confidence intervals (0.2-64.9 vs 0-99) reflect the variability in the underlying data. No specific adverse events or serious adverse events were reported in the provided data, and tolerability details were not included in the input.

The safety profile of the procedures was not explicitly detailed in the available data, as no specific adverse event rates or discontinuation numbers were reported. Consequently, a direct comparison of perioperative safety or long-term tolerability between the surgical techniques cannot be drawn from this specific dataset. The absence of reported safety data limits the ability to assess the risk-benefit profile beyond the primary survival endpoints.

These results align with broader trends in lung cancer surgery where sub-lobar resections are increasingly utilized for early-stage disease, though the specific context of neuroendocrine tumors requires careful consideration. The finding that wedge resection carries higher mortality suggests that this specific technique may not be equivalent to lobectomy or segmentectomy for this patient population. However, the lack of statistical significance between lobectomy and segmentectomy supports the potential use of segmentectomy as an alternative to lobectomy in select cases, provided adequate lymph node sampling is performed.

Methodological limitations inherent to meta-analyses of observational data or heterogeneous surgical series likely influence these conclusions. The wide confidence intervals observed in the lymph node sampling and upstaging outcomes suggest heterogeneity in how these procedures were performed or reported across the included studies. Potential biases related to patient selection, surgeon experience, and institutional protocols were not detailed in the input data. Furthermore, the inability to report specific adverse events limits the comprehensiveness of the safety assessment.

Clinically, these findings suggest that the choice between lobectomy and sub-lobar resection for lung neuroendocrine tumors should not rely solely on overall survival data, which shows equivalence between lobectomy and segmentectomy. Surgeons may consider sub-lobar techniques, particularly segmentectomy, for patients where lobectomy might be technically challenging, provided they are prepared for potentially lower rates of lymph node sampling. The higher mortality associated with wedge resection warrants caution, suggesting it may be reserved for specific scenarios where other options are contraindicated. Questions remain regarding the long-term oncologic outcomes beyond 60 months and the impact of specific pathological subtypes of neuroendocrine tumors on these surgical decisions.